A Pivotal Study of the Safety and Effectiveness of Arformoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Sumitomo Pharma

Status and phase: Completed; Phase 3

Conditions: COPD

Treatments: Drug: Placebo; Drug: Arformoterol tartrate inhalation solution; Drug: Salmeterol MDI

Study type: Interventional

Funder types: Industry

Identifiers

NCT00685841

091-050

Details and patient eligibility

About

A 12 week study to investigate the safety and effectiveness of arformoterol given twice daily compared to placebo in subjects with COPD.

Full description

This study is a double-blind, double-dummy, randomized, placebo- and active-controlled, multicenter, parallel-group study of adult subjects with a primary clinical diagnosis of COPD. Approximately 800 subjects were to be randomized in this study. Study participation consisted of a total of eight (8) study visits over approximately four (4) months for each subject. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.

Enrollment: 717 patients

Sex: All

Ages: 35+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

• Subject may be male or female and must be aged less than or equal to 35 years on the day the informed consent is signed.

• Female subjects greater than or equal to 65 years of age must have a serum pregnancy test conducted at Visit 1 and confirmed negative prior to randomization. Subjects of childbearing potential must be using an acceptable method of birth control.

• Female subjects who are considered not of childbearing potential must be:

  • documented surgically sterile (defined as status post-hysterectomy or bilateral tubal ligation) OR
  • postmenopausal

• Subject must have a primary diagnosis of COPD, which may include components of chronic bronchitis and/or emphysema. Diagnosis can be made during the screening process.

• Subject must have a minimum smoking history of 15 pack-years (pack-years = the number of cigarette packs per day times the number of years).

• Subject must have a chest x-ray that is consistent with the diagnosis of COPD (e.g., not diagnostic of pneumonia, other infection, atelectasis, or pneumothorax or other active/ongoing pulmonary conditions) and taken less than or equal to 3 months prior to study start. If there is no chest x-ray taken less than or equal to 3 months prior to study start, or if recent results are unavailable for review, a chest x-ray will be performed.

• Subject must be able to complete all study questionnaires and logs reliably. Exclusion Criteria

• Female subject who is pregnant or lactating.

• Subject who has participated in an investigational drug study within 30 days prior to study start, or who is currently participating in another investigational drug study.

• Subject whose schedule or travel prevents the completion of all required visits.

• Subject who is scheduled for in-patient hospitalization, including elective surgery (in patient or out-patient) during the trial.

• Subject with life-threatening/unstable respiratory status, including upper or lower respiratory tract infection, within the previous 30 days prior to study start.

• Subject with a known history of asthma or any chronic respiratory disease (including a current history of sleep apnea) other than COPD (chronic bronchitis and/or emphysema).

• Subject with a history of cancer except non-melanomatous skin cancer. Subjects with a history of cancer that is considered surgically cured and without a recurrence within the past 10 years may participate in the study. History of hematologic/lymphatic malignancy treated with chemotherapy or radiation is not allowed.

• Subject with a history of lung resection of more than one full lobe.

• Subject who requires continuous supplemental oxygen therapy (unless subject resides at elevation greater than or equal to 4,000 feet).

• Subject who has had a change in dose or type of any medications for COPD within 14 days prior to the screening visit.

• Subject with a known sensitivity to (R,R)-formoterol, ipratropium, salmeterol or albuterol or any of the excipients contained in any of these formulations.

• Subject with a history of substance abuse or drug abuse within 12 months of study start, or with a positive urine drug screen at study start.

• Subject using any prescription drug for which concomitant beta-agonist administration is contraindicated (e.g., beta-blockers).

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

717 participants in 5 patient groups, including a placebo group

A

Experimental group

Description:

Arformoterol 50 mcg QD and placebo MDI

Treatment:

Drug: Arformoterol tartrate inhalation solution

Drug: Arformoterol tartrate inhalation solution

Drug: Arformoterol tartrate inhalation solution

B

Experimental group

Description:

Arformoterol 25 mcg BID and placebo MDI

Treatment:

Drug: Arformoterol tartrate inhalation solution

Drug: Arformoterol tartrate inhalation solution

Drug: Arformoterol tartrate inhalation solution

C

Experimental group

Description:

Arformoterol 15 mcg BID and placebo MDI

Treatment:

Drug: Arformoterol tartrate inhalation solution

Drug: Arformoterol tartrate inhalation solution

Drug: Arformoterol tartrate inhalation solution

D

Active Comparator group

Description:

Salmeterol MDI 42 mcg BID and placebo inhalation solution

Treatment:

Drug: Salmeterol MDI

E

Placebo Comparator group

Description:

Placebo BID MDI and inhalation solution

Treatment:

Drug: Placebo